NICE backtracks on green light for Amgen's Xgeva after change of comparators
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is rethinking its initial draft yes for Amgen's bone drug Xgeva (denosumab) for preventing skeletal related events in prostate cancer patients with bone metastases. The draft no comes after NICE's appraisal committee decided that best supportive care would be a more suitable comparator in prostate cancer patients rather than bisphosphonates.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.